Literature DB >> 23797225

PET or PET/CT for detection of peritoneal carcinomatosis: a meta-analysis.

Ming-Che Chang1, Jin-Hua Chen, Ji-An Liang, Wen-Sheng Huang, Kai-Yuan Cheng, Chia-Hung Kao.   

Abstract

UNLABELLED: The present study assessed the diagnostic performances of (18)F-FDG PET or PET/CT in detecting peritoneal carcinomatosis in patients with cancer.
METHODS: Through a search of MEDLINE (January 1998 to September 2012), an overall weighted average for sensitivity and specificity was calculated using the weighted averages of the sample sizes in each relevant study. Pooled estimates of positive and negative likelihood ratios were calculated using fixed and random effects models, respectively, according to the heterogeneity among studies. A summary receiver operating characteristics (sROC) curve was constructed and the area under the sROC curve (AUC) was calculated. To explore heterogeneity, due to sources other than threshold effects, I-square was calculated.
RESULTS: The present study included analyses of patients (n = 513) from 7 studies. Results indicated a significant heterogeneity for sensitivity and specificity (I(2) > 50% and P < 0.05). The overall pooled estimates for sensitivity and specificity of FDG PET or PET/CT scans in the detection of peritoneal carcinomatosis were 72.4% (95% CI, 64.4%-79.5%) and 96.7% (95% CI, 94.4%-98.3%), respectively. The positive likelihood ratio was 10.414 (95% CI, 6.195-17.506) and the negative likelihood ratio 0.312 (95% CI, 0.159-0.612). The AUC was 0.9404. The overall diagnostic accuracy (Q* index) was 87.8%.
CONCLUSION: The high specificity may provide the reliability of a positive FDG PET or PET/CT to detect peritoneal carcinomatosis in patients with cancer. FDG PET or PET/CT has only weak power to exclude the presence of peritoneal carcinomatosis. By a good overall diagnostic accuracy, FDG PET or PET/CT may prove beneficial to surgeons when selecting appropriate patients on whom to perform laparoscopy or laparotomy.

Entities:  

Mesh:

Year:  2013        PMID: 23797225     DOI: 10.1097/RLU.0b013e318299609f

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  12 in total

Review 1.  Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?

Authors:  Camille L Stewart; Susanne Warner; Kaori Ito; Mustafa Raoof; Geena X Wu; Jonathan Kessler; Jae Y Kim; Yuman Fong
Journal:  Curr Probl Surg       Date:  2018-10-04       Impact factor: 1.909

2.  Impact of introduction of laparoscopic surgery on management of unresolved intra-abdominal malignancies in a West African hospital.

Authors:  Adewale O Adisa; Oladejo O Lawal; Abdul-Rasheed K Adesunkanmi; Olusanya Adejuyigbe
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

3.  Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT.

Authors:  Liang Zhao; Yizhen Pang; Zuoming Luo; Kaili Fu; Tingting Yang; Long Zhao; Long Sun; Hua Wu; Qin Lin; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-07       Impact factor: 9.236

Review 4.  Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis.

Authors:  Andrea Laghi; Davide Bellini; Marco Rengo; Fabio Accarpio; Damiano Caruso; Daniele Biacchi; Angelo Di Giorgio; Paolo Sammartino
Journal:  Radiol Med       Date:  2016-09-19       Impact factor: 3.469

5.  Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series.

Authors:  C Brendle; N F Schwenzer; H Rempp; H Schmidt; C Pfannenberg; C la Fougère; K Nikolaou; C Schraml
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-31       Impact factor: 9.236

6.  Intraperitoneal Glucose Transport to Micrometastasis: A Multimodal In Vivo Imaging Investigation in a Mouse Lymphoma Model.

Authors:  Zsombor Ritter; Katalin Zámbó; Xinkai Jia; Dávid Szöllősi; Dániel Dezső; Hussain Alizadeh; Ildikó Horváth; Nikolett Hegedűs; David Tuch; Kunal Vyas; Péter Balogh; Domokos Máthé; Erzsébet Schmidt
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

7.  Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.

Authors:  Nina R Sluiter; Koen P Rovers; Youssra Salhi; Stijn L Vlek; Veerle M H Coupé; Henk M W Verheul; Geert Kazemier; Ignace H J T de Hingh; Jurriaan B Tuynman
Journal:  Ann Surg Oncol       Date:  2018-05-31       Impact factor: 5.344

8.  Individualized multimodal treatment strategy for metastatic rectal adenocarcinoma: Case report.

Authors:  Helena Magalhães; Mário Fontes-Sousa; Manuel Fernandes; Manuela Machado
Journal:  Porto Biomed J       Date:  2018-07-03

9.  Postoperative oxaliplatin-based hyperthermic intraperitoneal chemotherapy: an effective and safe palliative treatment option for colorectal cancer with peritoneal metastasis.

Authors:  Tuanhe Sun; Kang Li; Gang Xu; Kun Zhu; Qiong Wang; Chengxue Dang; Dawei Yuan
Journal:  World J Surg Oncol       Date:  2021-07-06       Impact factor: 2.754

10.  Abdominal Sarcoidosis Mimicking Peritoneal Carcinomatosis.

Authors:  Won Seok Roh; Seungho Lee; Ji Hyun Park; Jeonghyun Kang
Journal:  Ann Coloproctol       Date:  2018-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.